Matches in Nanopublications for { ?s ?p "[Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP363545.RAZN7wopvzIyYswbWAKDCCj4diZxhxNC7man40VDm86T0130_assertion description "[Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP363545.RAZN7wopvzIyYswbWAKDCCj4diZxhxNC7man40VDm86T0130_provenance.
- NP977098.RAWLwOnyzpvOs8yOyZDRg4bJiAchx3RqxS1wtgkhBmW6A130_assertion description "[Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977098.RAWLwOnyzpvOs8yOyZDRg4bJiAchx3RqxS1wtgkhBmW6A130_provenance.
- NP867823.RAO9Ki8Aa_BZI6JmoLprzR4NIjK_p4CFPYRx27ZPVl_sc130_assertion description "[Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867823.RAO9Ki8Aa_BZI6JmoLprzR4NIjK_p4CFPYRx27ZPVl_sc130_provenance.
- NP847927.RAP5uaRNUKsDpgNFnkDY-slMPZW4SVDEoxt5Y5W4QzAR8130_assertion description "[Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP847927.RAP5uaRNUKsDpgNFnkDY-slMPZW4SVDEoxt5Y5W4QzAR8130_provenance.